{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+antipsychotic+therapy&page=2",
    "query": {
      "intervention": "Standard antipsychotic therapy",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 33,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+antipsychotic+therapy&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+antipsychotic+therapy&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-01T00:52:59.073Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00845026",
      "title": "A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "LY2140023",
          "type": "DRUG"
        },
        {
          "name": "aripiprazole",
          "type": "DRUG"
        },
        {
          "name": "olanzapine",
          "type": "DRUG"
        },
        {
          "name": "risperidone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Denovo Biopharma LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 261,
      "start_date": "2009-03",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2022-11-08",
      "last_synced_at": "2026-10-01T00:52:59.073Z",
      "location_count": 11,
      "location_summary": "Escondido, California • Garden Grove, California • Washington D.C., District of Columbia + 8 more",
      "locations": [
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Hoffman Estates",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00845026"
    },
    {
      "nct_id": "NCT02237417",
      "title": "Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Standard of Care Oral antipsychotics",
          "type": "DRUG"
        },
        {
          "name": "IM aripiprazole once monthly",
          "type": "DRUG"
        },
        {
          "name": "No Treatment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "18 Years to 35 Years"
      },
      "enrollment_count": 47,
      "start_date": "2014-09-01",
      "completion_date": "2020-07-30",
      "has_results": true,
      "last_update_posted_date": "2025-03-14",
      "last_synced_at": "2026-10-01T00:52:59.073Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02237417"
    },
    {
      "nct_id": "NCT07570875",
      "title": "Evaluating the Impact of Ketogenic Therapy on Symptom Severity and Metabolic Side Effect Profile Among Individuals Living With Bipolar Disorder in A Rural Southern Catchment Area",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Bipolar Disorder"
      ],
      "interventions": [
        {
          "name": "Ketogenic foodstuffs",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Standard of Care Oral antipsychotics",
          "type": "OTHER"
        },
        {
          "name": "Standard of care long acting injectable medication for bipolar disorder",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2026-10",
      "completion_date": "2027-10",
      "has_results": false,
      "last_update_posted_date": "2026-09-21",
      "last_synced_at": "2026-10-01T00:52:59.073Z",
      "location_count": 1,
      "location_summary": "Montgomery, Alabama",
      "locations": [
        {
          "city": "Montgomery",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07570875"
    },
    {
      "nct_id": "NCT00616798",
      "title": "A Study of RO4917838 in Combination With Antipsychotic Treatment in Patients With Schizophrenia.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "RO4917838",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Standard antipsychotic therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 323,
      "start_date": "2008-03",
      "completion_date": "2010-02",
      "has_results": false,
      "last_update_posted_date": "2014-06-24",
      "last_synced_at": "2026-10-01T00:52:59.073Z",
      "location_count": 14,
      "location_summary": "Granada Hills, California • Los Angeles, California • Oceanside, California + 10 more",
      "locations": [
        {
          "city": "Granada Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00616798"
    },
    {
      "nct_id": "NCT00406718",
      "title": "Improving Adherence to Oral Antipsychotic Medications in People With Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder"
      ],
      "interventions": [
        {
          "name": "Med-eMonitor",
          "type": "BEHAVIORAL"
        },
        {
          "name": "PharmCAT",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Treatment as Usual",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 197,
      "start_date": "2006-11",
      "completion_date": "2013-07",
      "has_results": true,
      "last_update_posted_date": "2015-10-05",
      "last_synced_at": "2026-10-01T00:52:59.073Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00406718"
    },
    {
      "nct_id": "NCT05402111",
      "title": "A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "SEP-363856",
          "type": "DRUG"
        },
        {
          "name": "Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 31,
      "start_date": "2022-06-13",
      "completion_date": "2023-09-27",
      "has_results": false,
      "last_update_posted_date": "2024-06-26",
      "last_synced_at": "2026-10-01T00:52:59.073Z",
      "location_count": 7,
      "location_summary": "Little Rock, Arkansas • Rogers, Arkansas • Long Beach, California + 4 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05402111"
    },
    {
      "nct_id": "NCT04280965",
      "title": "Quetiapine Augmentation of PE Therapy for the Treatment of Co-occurring PTSD and Mild Traumatic Brain Injury",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Post Traumatic Stress Disorder"
      ],
      "interventions": [
        {
          "name": "Quetiapine Fumarate",
          "type": "DRUG"
        },
        {
          "name": "Standard of care meducations",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2019-02-01",
      "completion_date": "2022-10-17",
      "has_results": false,
      "last_update_posted_date": "2023-05-09",
      "last_synced_at": "2026-10-01T00:52:59.073Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04280965"
    },
    {
      "nct_id": "NCT06482554",
      "title": "Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Apathy",
        "Schizophrenia",
        "Schizophrenia; Psychosis"
      ],
      "interventions": [
        {
          "name": "Lumateperone 42 mg",
          "type": "DRUG"
        },
        {
          "name": "Risperidone 2 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Louisiana State University Health Sciences Center Shreveport",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 80,
      "start_date": "2024-06",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2024-07-01",
      "last_synced_at": "2026-10-01T00:52:59.073Z",
      "location_count": 1,
      "location_summary": "Shreveport, Louisiana",
      "locations": [
        {
          "city": "Shreveport",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06482554"
    },
    {
      "nct_id": "NCT07184619",
      "title": "Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Treatment-resistant Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Evenamide 15 mg bid",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Newron Pharmaceuticals SPA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 400,
      "start_date": "2026-01-23",
      "completion_date": "2027-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-10",
      "last_synced_at": "2026-10-01T00:52:59.073Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Miami, Florida • Atlanta, Georgia + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07184619"
    },
    {
      "nct_id": "NCT00712270",
      "title": "Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in Schizophrenia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Aripiprazole",
          "type": "DRUG"
        },
        {
          "name": "Risperidone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kettering Health Network",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 21,
      "start_date": "2005-04",
      "completion_date": "2010-11",
      "has_results": true,
      "last_update_posted_date": "2020-07-28",
      "last_synced_at": "2026-10-01T00:52:59.073Z",
      "location_count": 1,
      "location_summary": "Kettering, Ohio",
      "locations": [
        {
          "city": "Kettering",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00712270"
    }
  ]
}